Abstract
Purpose of Review
Chronic kidney disease (CKD) is characterized by the accumulation of uremic retention solutes (URS) and is associated with perturbations of glucose homeostasis even in absence of diabetes. The underlying mechanisms of insulin resistance, β cell failure, and increase risk of diabetes in CKD, however, remain unclear. Metabolomic studies reported that some metabolites are similar in CKD and diabetic kidney disease (DKD) and contribute to the progression to end-stage renal disease. We attempted to discuss the mechanisms involved in the disruption of carbohydrate metabolism in CKD by focusing on the specific role of URS.
Recent Findings
Recent clinical data have demonstrated a defect of insulin secretion in CKD. Several studies highlighted the direct role of some URS (urea, trimethylamine N-oxide (TMAO), p-cresyl sulfate, 3-carboxylic acid 4-methyl-5-propyl-2-furan propionic (CMPF)) in glucose homeostasis abnormalities and diabetes incidence.
Summary
Gut dysbiosis has been identified as a potential contributor to diabetes and to the production of URS. The complex interplay between the gut microbiota, kidney, pancreas β cell, and peripheral insulin target tissues has brought out new hypotheses for the pathogenesis of CKD and DKD. The characterization of intestinal microbiota and its associated metabolites are likely to fill fundamental knowledge gaps leading to innovative research, clinical trials, and new treatments for CKD and DKD.
Similar content being viewed by others
References
Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance
Go AS, Chertow GM, Fan D, McCulloch CE, Hsu C. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med. 2004;351:1296–305.
Menon V, Greene T, Pereira AA, Wang X, Beck GJ, Kusek JW, et al. Glycosylated hemoglobin and mortality in patients with nondiabetic chronic kidney disease. J Am Soc Nephrol. 2005;16:3411–7.
Koppe L, Pelletier CC, Alix PM, Kalbacher E, Fouque D, Soulage CO, et al. Insulin resistance in chronic kidney disease: new lessons from experimental models. Nephrol Dial Transplant Off Publ Eur Dial Transpl Assoc - Eur Ren Assoc. 2014;29:1666–74.
• Sharma K, Karl B, Mathew AV, Gangoiti JA, Wassel CL, Saito R, et al. Metabolomics reveals signature of mitochondrial dysfunction in diabetic kidney disease. J Am Soc Nephrol. 2013;24:1901–12. This study present a large urine metabolomics study in diabetic kidney disease and identify potential biomarkers of diabetic complications.
Duranton F, Cohen G, De Smet R, Rodriguez M, Jankowski J, Vanholder R, et al. Normal and pathologic concentrations of uremic toxins. J Am Soc Nephrol. 2012;23:1258–70.
Eloot S, Schepers E, Barreto DV, Barreto FC, Liabeuf S, Van Biesen W, et al. Estimated glomerular filtration rate is a poor predictor of concentration for a broad range of uremic toxins. Clin J Am Soc Nephrol. 2011;6:1266–73.
Qin J, Li Y, Cai Z, Li S, Zhu J, Zhang F, et al. A metagenome-wide association study of gut microbiota in type 2 diabetes. Nature. 2012;490:55–60.
Caricilli AM, Picardi PK, de Abreu LL, Ueno M, Prada PO, Ropelle ER, et al. Gut microbiota is a key modulator of insulin resistance in TLR 2 knockout mice. Vidal-Puig AJ, editor. PLoS Biol. 2011;9:e1001212.
Cox AJ, West NP, Cripps AW. Obesity, inflammation, and the gut microbiota. Lancet Diabetes Endocrinol. 2015;3:207–15.
de Goffau MC, Fuentes S, van den Bogert B, Honkanen H, de Vos WM, Welling GW, et al. Aberrant gut microbiota composition at the onset of type 1 diabetes in young children. Diabetologia. 2014;57:1569–77.
Koppe L, Mafra D, Fouque D. Probiotics and chronic kidney disease. Kidney Int. 2015;88:958–66.
DeFronzo RA, Tobin JD, Rowe JW, Andres R. Glucose intolerance in uremia. Quantification of pancreatic beta cell sensitivity to glucose and tissue sensitivity to insulin. J Clin Invest. 1978;62:425–35.
DeFronzo RA, Alvestrand A, Smith D, Hendler R, Hendler E, Wahren J. Insulin resistance in uremia. J Clin Invest. 1981;67:563–8.
Friedman JE, Dohm GL, Elton CW, Rovira A, Chen JJ, Leggett-Frazier N, et al. Muscle insulin resistance in uremic humans: glucose transport, glucose transporters, and insulin receptors. Am J Phys. 1991;26:E87–94.
Chapagain A, Caton PW, Kieswich J, Andrikopoulos P, Nayuni N, Long JH, et al. Elevated hepatic 11β-hydroxysteroid dehydrogenase type 1 induces insulin resistance in uremia. Proc Natl Acad Sci U S A. 2014;111:3817–22.
Fadda GZ, Hajjar SM, Perna AF, Zhou XJ, Lipson LG, Massry SG. On the mechanism of impaired insulin secretion in chronic renal failure. J Clin Invest. 1991;87:255–61.
•• Koppe L, Nyam E, Vivot K, Manning Fox JE, Dai X-Q, Nguyen BN, et al. Urea impairs β cell glycolysis and insulin secretion in chronic kidney disease. J Clin Invest. 2016;126:3598–612. This study demonstrates the role of kidney disease and particular of urea in perturbation of insulin secretion associated with renal failure in mice and human islets.
Sui Y, Zhao H-L, Ma RCW, Ho CS, Kong APS, Lai FMM, et al. Pancreatic islet beta-cell deficit and glucose intolerance in rats with uninephrectomy. Cell Mol Life Sci CMLS. 2007;64:3119–28.
Nakamura Y, Yoshida T, Kajiyama S, Kitagawa Y, Kanatsuna T, Kondo M. Insulin release from column-perifused isolated islets of uremic rats. Nephron. 1985;40:467–9.
•• de Boer IH, Zelnick L, Afkarian M, Ayers E, Curtin L, Himmelfarb J, et al. Impaired glucose and insulin homeostasis in moderate-severe CKD. J Am Soc Nephrol. 2016;27:2861–71. This study shows a combination of insulin resistance and inadequate augmentation of insulin secretion led to an impaired of glucose tolerance in nondiabetic patients with CKD.
Idorn T, Knop FK, Jørgensen M, Holst JJ, Hornum M, Feldt-Rasmussen B. Gastrointestinal factors contribute to glucometabolic disturbances in nondiabetic patients with end-stage renal disease. Kidney Int. 2013;83:915–23.
Alvestrand A, Mujagic M, Wajngot A, Efendic S. Glucose intolerance in uremic patients: the relative contributions of impaired beta-cell function and insulin resistance. Clin Nephrol. 1989;3:175–83.
Kanauchi M, Akai Y, Hashimoto T. Validation of simple indices to assess insulin sensitivity and pancreatic Beta-cell function in patients with renal dysfunction. Nephron. 2002;92:713–5.
Meier JJ, Nauck MA, Kranz D, Holst JJ, Deacon CF, Gaeckler D, et al. Secretion, degradation, and elimination of glucagon-like peptide 1 and gastric inhibitory polypeptide in patients with chronic renal insufficiency and healthy control subjects. Diabetes. 2004;53:654–62.
Sechi LA, Catena C, Zingaro L, Melis A, Marchi SD. Abnormalities of glucose metabolism in patients with early renal failure. Diabetes. 2002;51:1226–32.
• Jia T, Risérus U, Xu H, Lindholm B, Arnlöv J, Sjögren P, et al. Kidney function, β-cell function and glucose tolerance in older men. J Clin Endocrinol Metab. 2014;100:587–93. This study shows in a large cohort of patients with CKD by euglycaemic hyperinsulinaemic clamp that β-cell function appropriately compensated the loss in insulin sensitivity.
• Pham H, Robinson-Cohen C, Biggs ML, Ix JH, Mukamal KJ, Fried LF, et al. Chronic kidney disease, insulin resistance, and incident diabetes in older adults. Clin J Am Soc Nephrol. 2012;7:588–94. This study observes that renal failure was associated with insulin resistance and β cell function was appropriately augmented and incident diabetes were not increased.
Allegra V, Mengozzi G, Martimbianco L, Vasile A. Glucose-induced insulin secretion in uremia: effects of aminophylline infusion and glucose loads. Kidney Int. 1990;38:1146–50.
Mak RH. Effect of metabolic acidosis on insulin action and secretion in uremia. Kidney Int. 1998;54:603–7.
Hampers CL, Soeldner JS, Doak PB, Merrill JP. Effect of chronic renal failure and hemodialysis on carbohydrate metabolism. J Clin Invest. 1966;45:1719–31.
Mak RH. 1,25-Dihydroxyvitamin D3 corrects insulin and lipid abnormalities in uremia. Kidney Int. 1998;53:1353–7.
Mak RH, Bettinelli A, Turner C, Haycock GB, Chantler C. The influence of hyperparathyroidism on glucose metabolism in uremia. J Clin Endocrinol Metab. 1985;60:229–33.
Nerpin E, Risérus U, Ingelsson E, Sundström J, Jobs M, et al. Insulin sensitivity measured with euglycemic clamp is independently associated with glomerular filtration rate in a community-based cohort. Diabetes Care. 2008;31:1550–5.
Flier JS, Minaker KL, Landsberg L, Young JB, Pallotta J, Rowe JW. Impaired in vivo insulin clearance in patients with severe target-cell resistance to insulin. Diabetes. 1982;31:132–5.
Fliser D, Pacini G, Engelleiter R, Kautzky-Willer A, Prager R, Franek E, et al. Insulin resistance and hyperinsulinemia are already present in patients with incipient renal disease. Kidney Int. 1998;53:1343–7.
Trirogoff ML, Shintani A, Himmelfarb J, Ikizler TA. Body mass index and fat mass are the primary correlates of insulin resistance in nondiabetic stage 3-4 chronic kidney disease patients. Am J Clin Nutr. 2007;86:1642–8.
Gnudi L, Coward RJM, Long DA. Diabetic nephropathy: perspective on novel molecular mechanisms. Trends Endocrinol Metab. 2016;27:820–30.
Artunc F, Schleicher E, Weigert C, Fritsche A, Stefan N, Häring H-U. The impact of insulin resistance on the kidney and vasculature. Nat Rev Nephrol. 2016;12:721–37.
Lorenzo C, Nath SD, Hanley AJG, Abboud HE, Gelfond JAL, Haffner SM. Risk of type 2 diabetes among individuals with high and low glomerular filtration rates. Diabetologia. 2009;52:1290–7.
Sahakyan K, Lee KE, Shankar A, Klein R. Serum cystatin C and the incidence of type 2 diabetes mellitus. Diabetologia. 2011;54:1335–40.
•• Xie Y, Bowe B, Li T, Xian H, Yan Y, Al-Aly Z. Higher blood urea nitrogen is associated with increased risk of incident diabetes mellitus. Kidney Int. 2018;93:741–52. This study shows in more than 1 million on USA veterans that higher levels of urea and lower glomerular filtration rate are associated with increased risk of incident diabetes.
Werder AA, Amos MA, Nielsen AH, Wolfe GH. Comparative effects of germfree and ambient environments on the development of cystic kidney disease in CFWwd mice. J Lab Clin Med. 1984;103:399–407.
Aronov PA, Luo FJ-G, Plummer NS, Quan Z, Holmes S, Hostetter TH, et al. Colonic contribution to uremic solutes. J Am Soc Nephrol. 2011;22:1769–76.
• Mishima E, Fukuda S, Mukawa C, Yuri A, Kanemitsu Y, Matsumoto Y, et al. Evaluation of the impact of gut microbiota on uremic solute accumulation by a CE-TOFMS-based metabolomics approach. Kidney Int. 2017;92:634–45. Using germ-free mice models, this study has determined the role of intestinal microbiota on uremic toxins production.
Le Chatelier E, Nielsen T, Qin J, Prifti E, Hildebrand F, Falony G, et al. Richness of human gut microbiome correlates with metabolic markers. Nature. 2013;500:541–6.
Bäckhed F, Manchester JK, Semenkovich CF, Gordon JI. Mechanisms underlying the resistance to diet-induced obesity in germ-free mice. Proc Natl Acad Sci U S A. 2007;104:979–84.
Caesar R, Reigstad CS, Bäckhed HK, Reinhardt C, Ketonen M, Lundén GÖ, et al. Gut-derived lipopolysaccharide augments adipose macrophage accumulation but is not essential for impaired glucose or insulin tolerance in mice. Gut. 2012;61:1701–7.
Vanholder R, Pletinck A, Schepers E, Glorieux G. Biochemical and clinical impact of organic uremic retention solutes: a comprehensive update. Toxins. 2018;8:10.
Tang WHW, Wang Z, Levison BS, Koeth RA, Britt EB, Fu X, et al. Intestinal microbial metabolism of phosphatidylcholine and cardiovascular risk. N Engl J Med. 2013;368:1575–84.
Kim RB, Morse BL, Djurdjev O, Tang M, Muirhead N, Barrett B, et al. Advanced chronic kidney disease populations have elevated trimethylamine N-oxide levels associated with increased cardiovascular events. Kidney Int. 2016;89:1144–52.
Xu K-Y, Xia G-H, Lu J-Q, Chen M-X, Zhen X, Wang S, et al. Impaired renal function and dysbiosis of gut microbiota contribute to increased trimethylamine-N-oxide in chronic kidney disease patients. Sci Rep. 2017;7:1445.
Kikuchi M, Ueno M, Itoh Y, Suda W, Hattori M. Uremic toxin-producing gut microbiota in rats with chronic kidney disease. Nephron. 2017;135:51–60.
• van der Kloet FM, Tempels FWA, Ismail N, van der Heijden R, Kasper PT, Rojas-Cherto M, et al. Discovery of early-stage biomarkers for diabetic kidney disease using ms-based metabolomics (FinnDiane study). Metabolomics. 2012;8:109–19. This study shows that changes in some uremic toxins in urine measured by metabolomics analyze are predictive of significant rise in albumin excretion rate in type 1 diabetes patients.
• Niewczas MA, Sirich TL, Mathew AV, Skupien J, Mohney RP, Warram JH, et al. Uremic solutes and risk of end-stage renal disease in type 2 diabetes: metabolomic study. Kidney Int. 2014;85:1214–24. This study is a large metabolomic study that has described abnormal plasma concentrations of uremic solutes either contribute to progression to end stage renal disease in type 2 diabetes.
Wong J, Piceno YM, Desantis TZ, Pahl M, Andersen GL, Vaziri ND. Expansion of urease- and uricase-containing, indole- and p-cresol-forming and contraction of short-chain fatty acid-producing intestinal microbiota in ESRD. Am J Nephrol. 2014;39:230–7.
Vaziri ND, Yuan J, Norris K. Role of urea in intestinal barrier dysfunction and disruption of epithelial tight junction in chronic kidney disease. Am J Nephrol. 2013;37:1–6.
Wang F, Zhang P, Jiang H, Cheng S. Gut bacterial translocation contributes to microinflammation in experimental uremia. Dig Dis Sci. 2012;57:2856–62.
Wang F, Jiang H, Shi K, Ren Y, Zhang P, Cheng S. Gut bacterial translocation is associated with microinflammation in end-stage renal disease patients. Nephrol Carlton Vic. 2012;17:733–8.
Vaziri ND, Dure-Smith B, Miller R, Mirahmadi MK. Pathology of gastrointestinal tract in chronic hemodialysis patients: an autopsy study of 78 cases. Am J Gastroenterol. 1985;80:608–11.
Vanholder R, Schepers E, Pletinck A, Nagler EV, Glorieux G. The uremic toxicity of indoxyl sulfate and p-cresyl sulfate: a systematic review. J Am Soc Nephrol. 2014;25:1897–907.
Zhao T, Zhang H, Zhao T, Zhang X, Lu J, Yin T, et al. Intrarenal metabolomics reveals the association of local organic toxins with the progression of diabetic kidney disease. J Pharm Biomed Anal. 2012;60:32–43.
Andrade-Oliveira V, Amano MT, Correa-Costa M, Castoldi A, Felizardo RJF, de Almeida DC, et al. Gut Bacteria products prevent AKI induced by ischemia-reperfusion. J Am Soc Nephrol. 2015;26:1877–88.
Nigam SK, Wu W, Bush KT, Hoenig MP, Blantz RC, Bhatnagar V. Handling of drugs, metabolites, and uremic toxins by kidney proximal tubule drug transporters. Clin J Am Soc Nephrol. 2015;10:2039–49.
Koppe L, Fouque D. Microbiota and prebiotics modulation of uremic toxin generation. Panminerva Med. 2017;59:173–87.
McCaleb ML, Izzo MS, Lockwood DH. Characterization and partial purification of a factor from uremic human serum that induces insulin resistance. J Clin Invest. 1985;75:391–6.
Raubenheimer PJ, Nyirenda MJ, Walker BR. A choline-deficient diet exacerbates fatty liver but attenuates insulin resistance and glucose intolerance in mice fed a high-fat diet. Diabetes. 2006;55:2015–20.
Schugar RC, Shih DM, Warrier M, Helsley RN, Burrows A, Ferguson D, et al. The TMAO-producing enzyme Flavin-containing monooxygenase 3 regulates obesity and the Beiging of white adipose tissue. Cell Rep. 2017;19:2451–61.
Koppe L, Pillon NJ, Vella RE, Croze ML, Pelletier CC, Chambert S, et al. p-Cresyl sulfate promotes insulin resistance associated with CKD. J Am Soc Nephrol. 2013;24:88–99.
Koppe L, Alix PM, Croze ML, Chambert S, Vanholder R, Glorieux G, et al. P-Cresyl glucuronide is a major metabolite of p-cresol in mouse: in contrast to p-cresyl sulphate, p-cresyl glucuronide fails to promote insulin resistance. Nephrol Dial Transplant. 2017;32:2000–9.
Minakuchi H, Wakino S, Hosoya K, Sueyasu K, Hasegawa K, Shinozuka K, et al. The role of adipose tissue asymmetric dimethylarginine/dimethylarginine dimethylaminohydrolase pathway in adipose tissue phenotype and metabolic abnormalities in subtotally nephrectomized rats. Nephrol Dial Transplant. 2016;31:413–23.
Pelantová H, Bugáňová M, Holubová M, Šedivá B, Zemenová J, Sýkora D, et al. Urinary metabolomic profiling in mice with diet-induced obesity and type 2 diabetes mellitus after treatment with metformin, vildagliptin and their combination. Mol Cell Endocrinol. 2016;431:88–100.
Wu H, Esteve E, Tremaroli V, Khan MT, Caesar R, Mannerås-Holm L, et al. Metformin alters the gut microbiome of individuals with treatment-naive type 2 diabetes, contributing to the therapeutic effects of the drug. Nat Med. 2017;23:850–8.
Cani PD, Amar J, Iglesias MA, Poggi M, Knauf C, Bastelica D, et al. Metabolic endotoxemia initiates obesity and insulin resistance. Diabetes. 2007;56:1761–72.
Gomes JMG, Costa JA, Alfenas RCG. Metabolic endotoxemia and diabetes mellitus: a systematic review. Metabolism. 2017;68:133–44.
Ríos-Covián D, Ruas-Madiedo P, Margolles A, Gueimonde M, Reyes-Gavilán DL, et al. Intestinal short chain fatty acids and their link with diet and human health. Front Microbiol. 2016;7:185.
Zhao L, Zhang F, Ding X, Wu G, Lam YY, et al. Gut bacteria selectively promoted by dietary fibers alleviate type 2 diabetes. Science. 2018;359:1151–6.
• D’Apolito M, Du X, Zong H, Catucci A, Maiuri L, Trivisano T, et al. Urea-induced ROS generation causes insulin resistance in mice with chronic renal failure. J Clin Invest. 2010;120:203–13. This study demonstrates the role of urea in insulin resistance in rodent and cell models.
• Prentice KJ, Luu L, Allister EM, Liu Y, Jun LS, Sloop KW, et al. The furan fatty acid metabolite CMPF is elevated in diabetes and induces β cell dysfunction. Cell Metab. 2014;19:653–66. This study shows that CMPF a metabolite increase in diabete and renal desease is involved in β-Ccell dysfunction.
Gruppen EG, Garcia E, Connelly MA, Jeyarajah EJ, Otvos JD, Bakker SJL, et al. TMAO is associated with mortality: impact of modestly impaired renal function. Sci Rep. 2017;7:13781.
Heianza Y, Sun D, Li X, DiDonato JA, Bray GA, Sacks FM, et al. Gut microbiota metabolites, amino acid metabolites and improvements in insulin sensitivity and glucose metabolism: the POUNDS lost trial. Gut. 2018; https://doi.org/10.1136/gutjnl-2018-316155.
Poesen R, Evenepoel P, de Loor H, Delcour JA, Courtin CM, Kuypers D, et al. The influence of prebiotic Arabinoxylan oligosaccharides on microbiota derived uremic retention solutes in patients with chronic kidney disease: a randomized controlled trial. PLoS One. 2016;11:e0153893.
Chiu C-A, Lu L-F, Yu T-H, Hung W-C, Chung F-M, Tsai I-T, et al. Increased levels of total P-Cresylsulphate and indoxyl sulphate are associated with coronary artery disease in patients with diabetic nephropathy. Rev Diabet Stud. 2010;7:275–84.
Roh E, Kwak SH, Jung HS, Cho YM, Pak YK, Park KS, et al. Serum aryl hydrocarbon receptor ligand activity is associated with insulin resistance and resulting type 2 diabetes. Acta Diabetol. 2015;52:489–95.
Zhang A, Sun H, Yan G, Yuan Y, Han Y, Wang X. Metabolomics study of type 2 diabetes using ultra-performance LC-ESI/quadrupole-TOF high-definition MS coupled with pattern recognition methods. J Physiol Biochem. 2014;70:117–28.
Atoh K, Itoh H, Haneda M. Serum indoxyl sulfate levels in patients with diabetic nephropathy: relation to renal function. Diabetes Res Clin Pract. 2009;83:220–6.
Creely SJ, McTernan PG, Kusminski CM, Fisher fM, Da Silva NF, Khanolkar M, et al. Lipopolysaccharide activates an innate immune system response in human adipose tissue in obesity and type 2 diabetes. Am J Physiol Endocrinol Metab. 2007;292:E740–7.
Koppe L, Poitout V. CMPF: a biomarker for type 2 diabetes mellitus progression? Trends Endocrinol Metab. 2016;27:439–40.
Lankinen MA, Hanhineva K, Kolehmainen M, Lehtonen M, Auriola S, Mykkänen H, et al. CMPF does not associate with impaired glucose metabolism in individuals with features of metabolic syndrome. PLoS One. 2015;10:e0124379.
Luce M, Bouchara A, Pastural M, Granjon S, Szelag JC, Laville M, et al. Is 3-Carboxy-4-methyl-5-propyl-2-furanpropionate (CMPF) a clinically relevant uremic toxin in haemodialysis patients? Toxins. 2018;10. https://doi.org/10.3390/toxins10050205.
Retnakaran R, Ye C, Kramer CK, Connelly PW, Hanley AJ, Sermer M, et al. Evaluation of circulating determinants of Beta-cell function in women with and without gestational diabetes. J Clin Endocrinol Metab. 2016;101:2683–91.
Liu Y, Prentice KJ, Eversley JA, Hu C, Batchuluun B, Leavey K, et al. Rapid elevation in CMPF may act as a tipping point in diabetes development. Cell Rep. 2016;14:2889–900.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of Interest
L. Koppe and C.O. Soulage declare that they have no conflict of interest.
D. Fouque received honoraria and travel support from Fresenius Kabi, which markets a ketoanalogue supplement.
Human and Animal Rights and Informed Consent
This article does not contain any studies with human or animal subjects performed by any of the authors.
Additional information
This article is part of the Topical Collection on Microvascular Complications—Nephropathy
Rights and permissions
About this article
Cite this article
Koppe, L., Fouque, D. & Soulage, C.O. Metabolic Abnormalities in Diabetes and Kidney Disease: Role of Uremic Toxins. Curr Diab Rep 18, 97 (2018). https://doi.org/10.1007/s11892-018-1064-7
Published:
DOI: https://doi.org/10.1007/s11892-018-1064-7